Khalil Softa is an accomplished Medical Laboratory Senior Specialist with over 19 years of experience in clinical laboratory sciences and procurement management. Holding a master’s degree in medical laboratory sciences, a diploma in procurement, and certified health care supply chain manager with mini-MBA executive certification from London school of business, Khalil has built a robust career marked by excellence in laboratory operations, strategic procurement, and leadership within the healthcare sector. Currently serving as the Medical Laboratory Category Manager at the National Unified Procurement Co. (NUPCO) in Riyadh, Khalil leads procurement activities related to medical laboratories, managing tenders, designing the supply chain for lab supplies and services with different procurement and contract strategies (GPPRR, Reagent deal, framework agreements), and ensuring compliance with industry standards. Prior to this role, Khalil spent 15 years at PSMMC Central Laboratory, where he held the position of Chief of Medical Laboratory Scientific Officers (CMLSO). In this capacity, Khalil was responsible for overseeing the Clinical Chemistry Division, supervising the Total Lab automation (TLA), training laboratory staff, and ensuring the accuracy, quality, and reliability of lab results. Recognized for their meticulous attention to detail and a strong ability to communicate effectively with healthcare professionals, Khalil has a reputation for high-quality outputs and timely completion of laboratory assays. A certified CBAHI Surveyor and CAP inspector, contributing to advancements in laboratory practices. Excellent speaking in both English and Arabic, and possessing strong technical skills in laboratory IT systems, Khalil excels in fast-paced environments and fosters collaborative relationships with colleagues, medical laboratory market, and stakeholders. With a passion for continuous improvement, Khalil remains committed to enhancing laboratory services and health care supply chain efficiency within the healthcare industry.

Hesham is a seasoned physician-scientist who uniquely combines his personal experience with deep clinical expertise to identify transformational opportunities for advancing cancer care and treatment. With over 20 years in global research, Hesham has held senior positions in multiple global pharmaceutical companies, and has successfully led the development and registration of 12 precision oncology products and set numerous drug development precedents. His expertise encompasses both early and late stages of development across solid tumors, and hematological malignancies. Under his leadership, GSK’s Oncology Therapeutic Area has established a portfolio of cornerstone assets, transforming promising molecules into effective medicines. Hesham oversees more than 300 researchers around the world and leads the development of GSK’s Oncology pipeline of more than 15 clinical-stage assets targeting patient populations with high unmet needs. Hesham utilizes innovative translational approaches and advanced technologies like artificial intelligence, digital pathology, and tumor modeling, to advance the development of GSK’s next generation of cancer therapies. Hesham applies patient data driven approaches that lead to the development of medicines that make a meaningful difference in patients’ lives. With roots deeply tied to the Middle East, Hesham has led efforts to promote clinical studies in the region, and he has spearheaded initiatives to promote research and clinical trials within the Middle East, driving collaborative efforts with local oncology teams to research precision medicine and data driven approaches to cancer treatments. Hesham holds an MD from the University of Cairo School of Medicine and a Master’s degree in Regulatory Sciences from the University of Southern California (USC). He is currently pursuing a Doctoral degree in Regulatory Sciences at USC